|Day Low/High||3.54 / 3.65|
|52 Wk Low/High||3.18 / 10.98|
EMA Confirms Single HER2CLIMB Trial, If Positive, Could Support Approval
Investors in Cascadian Therapeutics Inc saw new options become available this week, for the February 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Preclinical data from Chk1 inhibitor program and first presentation characterizing lead TIGIT antibody
Cascadian's tucatinib delays regrowth of breast cancer by a median of 7.8 months in newly updated study results presented this week.
Poster session at ESMO 2016 Congress reviews evidence of clinical activity in patients with skin metastases
Special meeting to be held November 18, 2016 to seek stockholder approval
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.